Table 11.2.1.3 Open in new tab...

Table 11.2.1.3

Comparative efficacy of tamoxifen followed by a switch to an aromatase inhibitor versus tamoxifen alone

Study	IES	ARNO 95	ITA	ABCSG 8
Number of patients	4724	979	448	3714
Median follow-up	55.7 months	30.1 months	64 months	72 months
Disease-free survival	HR 0.76 p = 0.0001	HR 0.66 p = 0.49	HR 0.56 p = 0.01	HR 0.79 p = 0.038
Overall survival	HR 0.83^a p = 0.05	HR 0.53 p = 0.045	HR 0.56 p = 0.1	HR 0.77 p = 0.025

Study	IES	ARNO 95	ITA	ABCSG 8
Number of patients	4724	979	448	3714
Median follow-up	55.7 months	30.1 months	64 months	72 months
Disease-free survival	HR 0.76 p = 0.0001	HR 0.66 p = 0.49	HR 0.56 p = 0.01	HR 0.79 p = 0.038
Overall survival	HR 0.83^a p = 0.05	HR 0.53 p = 0.045	HR 0.56 p = 0.1	HR 0.77 p = 0.025

ABCSG, Austrian Breast and Colorectal Cancer Study Group; ARNO, Arimidex Nolvadex; HR, hazard ratio; IES, Intergroup Exemestane Study; ITA, Italian Tamoxifen Anastrozole.

In a subset of oestrogen receptor-positive patients only.

p ≤0.05 = significant.

This Feature Is Available To Subscribers Only